Literature DB >> 7737302

Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes.

N Kerlero de Rosbo1, I Mendel, A Ben-Nun.   

Abstract

Myelin basic protein (MBP) and proteolipid protein (PLP), the most abundant proteins of central nervous system (CNS) myelin, have been extensively studied as possible primary target antigens in multiple sclerosis (MS), a primary demyelinating autoimmune disease of the CNS. However, there is increasing evidence to suggest that autoimmune reactivity against the quantitatively minor myelin component, myelin oligodendrocyte glycoprotein (MOG), can also play a role in the pathogenicity of MS. We recently demonstrated a predominant response to MOG by peripheral blood lymphocytes from patients with MS tested for their reactivity against various myelin antigens, including MBP and PLP. To ascertain whether or not T cell reactivity to MOG in MS is a potentially pathogenic response, we have tested the ability of synthetic MOG peptides (pMOG) representing potential T cell epitopes, to induce neurological disease in mice. Both strains of mice tested (SJL/J and PL/J mice) were able to mount a primary T cell response to some of the five MOG peptides synthesized, pMOG 1-21, 35-55, 67-87, 104-117 and 202-218. T cell lines could be raised in both strains to pMOG 35-55 and 67-87, but epitope definition revealed that each strain recognized a different minimal epitope within these two peptides. T cell lines to pMOG 1-21 and 202-218 could also be raised in SJL/J and PL/J mice, respectively. T cell reactivity to pMOG 104-117 was not observed in either mouse strain. None of the peptides tested induced detectable clinical signs in SJL/J mice. In contrast, an MS-like chronic relapsing-remitting disease could be induced in PL/J mice with pMOG 35-55. The disease presented with a delayed onset and with clinical signs which differed significantly in their progression and expression from the typical ascending paralysis of experimental autoimmune encephalomyelitis induced with other myelin components, such as MBP and PLP. Histological examination of CNS tissue from mice injected with pMOG 35-55 revealed only mild neuropathological signs with few inflammatory foci in brain and spinal cord. Some myelin splitting and edema were detected upon electron microscopic examination in the spinal cord and cerebellum. Transfer of pMOG 35-55 reactive T cells into naive PL/J mice resulted in pathological changes characterized by inflammatory foci in the brain and spinal cord. This passively induced disease was clinically silent, as was also reported for Lewis rats injected with T cells specific for the same MOG peptide.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737302     DOI: 10.1002/eji.1830250419

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  30 in total

1.  Reversal of the CD4(+)/CD8(+) T-cell ratio in lymph node cells upon in vitro mitogenic stimulation by highly purified, water-soluble S3-S4 dimer of pertussis toxin.

Authors:  R Latif; N Kerlero de Rosbo; T Amarant; R Rappuoli; G Sappler; A Ben-Nun
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies.

Authors:  J Fisher; H Levkovitch-Verbin; H Schori; E Yoles; O Butovsky; J F Kaye; A Ben-Nun; M Schwartz
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

3.  Disease stage-dependent relationship between diffusion tensor imaging and electrophysiology of the visual system in a murine model of multiple sclerosis.

Authors:  Christopher Nishioka; Hsiao-Fang Liang; Chen-Fang Chung; Shu-Wei Sun
Journal:  Neuroradiology       Date:  2017-08-24       Impact factor: 2.804

Review 4.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

5.  The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.

Authors:  A Ben-Nun; I Mendel; R Bakimer; M Fridkis-Hareli; D Teitelbaum; R Arnon; M Sela; N Kerlero de Rosbo
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

Review 6.  New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  R Arnon; M Sela; D Teitelbaum
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

7.  Physical mapping of the human and mouse MOG gene at the distal end of the MHC class Ib region.

Authors:  D Pham-Dinh; E P Jones; G Pitiot; B Della Gaspera; P Daubas; J Mallet; D Le Paslier; K Fischer Lindahl; A Dautigny
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

Review 8.  Peptide vaccines in cancer-old concept revisited.

Authors:  Takumi Kumai; Hiroya Kobayashi; Yasuaki Harabuchi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2016-12-09       Impact factor: 7.486

9.  Novel pathogenic epitopes of myelin oligodendrocyte glycoprotein induce experimental autoimmune encephalomyelitis in C57BL/6 mice.

Authors:  Cecile Delarasse; Paul Smith; David Baker; Sandra Amor
Journal:  Immunology       Date:  2013-12       Impact factor: 7.397

10.  IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production.

Authors:  Jinbo Liu; Feng Lin; Michael G Strainic; Fengqi An; Robert H Miller; Cengiz Z Altuntas; Peter S Heeger; Vincent K Tuohy; M Edward Medof
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.